Table 1.
Baseline characteristics
| Control | AdVEGF-D | P-value | |
|---|---|---|---|
| n = 6 | n = 24 | ||
| Demographics | |||
| Sex (male/female) | 5/1 (83%/17%) | 23/1 (96%/4%) | 0.67 |
| Age (years) | 70 ± 6 | 71 ± 6 | 0.40 |
| CCS-class | 2.67 ± 0.52 | 2.83 ± 0.38 | 0.56 |
| Medical history | |||
| Previous MI | 4 (67) | 17 (71) | 0.60 |
| Previous CABG | 6 (100) | 23 (96) | 0.80 |
| Previous PCI | 3 (50) | 15 (63) | 0.46 |
| Family history of CAD | 5 (83) | 19 (79) | 0.66 |
| Hypertension | 6 (100) | 22 (92) | 0.63 |
| Hypercholesterolaemia | 6 (100) | 23 (96) | 0.80 |
| Smoker (current/ex) | 0/4 (0/67) | 0/17 (0/71) | 0.90 |
| Diabetes | 3 (50) | 12 (50) | 1.00 |
| Drug therapy | |||
| Aspirin | 5 (83) | 22 (92) | 0.51 |
| Clopidogrel | 3 (50) | 12 (50) | 1.00 |
| Warfarin | 2 (33) | 8 (33) | 1.00 |
| B-blockers | 6 (100) | 24 (100) | 1.00 |
| ACEI/ARB | 6 (100) | 21 (88) | 0.49 |
| Statins | 5 (83) | 24 (100) | 0.20 |
| Long-acting nitrates | 5 (83) | 23 (96) | 0.37 |
Mean ± SD or n (%).
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.